Papillary renal cell carcinoma: Current progress and future directions

Clinical Genitourinary Cancer

Volumn 12, Issue 2, 2014, Pages 74-79

  Twardowski, Przemyslaw W ^a,b   Mack, Philip C ^b,c   Lara Jr , Primo N ^b,c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Southwest Oncology Group   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ARQ197; EGFR pathway; Erlotinib; MET pathway; Tivantinib

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SCATTER FACTOR RECEPTOR; VASCULOTROPIN INHIBITOR;

CANCER CHEMOTHERAPY; CANCER GENETICS; CHROMOSOME ANALYSIS; CLINICAL TRIAL (TOPIC); CYTOGENETICS; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; HEREDITY; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; PAPILLARY CARCINOMA; PAPILLARY RENAL CELL CARCINOMA; REVIEW; SIGNAL TRANSDUCTION;

ARQ197; EGFR PATHWAY; ERLOTINIB; MET PATHWAY; TIVANTINIB;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84896354741     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.11.013     Document Type: Review

References (30)

1. B.I. Rini, S.C. Cambell, and B. Escudier Renal cell carcinoma Lancet 373 2009 1119 1132.
2. A. Pai, A. Brunson, and M. Brown et al. Evolving epidemiologic trends in nonclear cell renal cell cancer: an analysis of the California Cancer Registry Urology 82 2013 840 845.
3. B. Delahunt, and J.N. Eble Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors Mod Pathol 10 1997 537 544.
4. N. Kuroda, M. Toi, and M. Hiroi et al. Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects Histol Histopathol 18 2003 487 494.
5. T. Kosaka, S. Mikami, and A. Miyajima et al. Papillary renal cell carcinoma: clinicopathological characteristics in 40 patients Clin Exp Nephrol 12 2008 195 199.
6. W.M. Linehan, G. Bratslavsky, and P.A. Pinto et al. Molecular diagnosis and therapy of kidney cancer Ann Rev Med 61 2010 329 343.
7. L. Schmidt, F.M. Duh, and F. Chen et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat Genet 16 1997 68 73.
8. M. Kuru, V. Launonen, and M. Hietala et al. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology Am J Pathol 159 2001 852 859.
9. R.L. Grubb 3rd, M.E. Franks, and J. Toro et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer J Urol 177 2007 2074 2079.
10. D. Cohen, and M. Zhou Molecular genetics of familial renal cell carcinoma syndromes Clin Lab Med 25 2005 259 277.
11. J.S. Isaacs, Y.J. Jung, and D.R. Mole et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability Cancer Cell 8 2005 143 153.
12. L. Schmidt, K. Junker, and N. Nakaigawa et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas Oncogene 18 1999 2343 2350.
13. E.C. Pfafenroth, and W.M. Linehan Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy Expert Opin Biol Ther 8 2008 779 790.
14. M.E. Gore, C. Szczylik, and M. Porta et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 758 763.
15. E.R. Plimack, E. Jonasch, and B.N. Bekele et al. Sunitinib in non-clear cell renal cell carcinoma: a phase II study J Clin Oncol 26 suppl 2008 (abstract 5112).
16. T.K. Choueiri, A. Plantade, and P. Elson et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 2008 127 131.
17. W. Stadler, R. Figlin, and D. McDermott et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Cancer 116 2010 1272 1280.
18. B. Escudier, S. Ravaud, and S. Negrier et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (pharmacokinetic) analysis J Clin Oncol 26 suppl 15S 2008 (abstract 5025).
19. G. Hudes, M. Carducci, and P. Tomczak et al. Temsirolimus, interferon alfa or both for advanced renal cell carcinoma N Engl J Med 356 2007 2271 2281.
20. B. Escudier, S. Bracarda, and J.P. Maroto et al. Open-label phase II trial of first-line everolimus monotherapy in patients with advanced papillary renal cell carcinoma. RAPTOR final analysis European Cancer Congress 2013 abstract 2706.
21. C. Blank, P. Bono, and J. Larkin et al. Safety and efficacy of everolimus in patinets with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy. Subgroup analysis of REACT J Clin Oncol 30 suppl 5 2012 (abstract 402).
22. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma N Engl J Med 356 2007 115 124.
23. S.F. Bellon, P. Kaplan-Lefko, and Y. Yang et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations J Biol Chem 283 2008 2675 2683.
24. T.K. Choueri, U. Vaishampayan, and J.E. Rosenberg et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretenib in patients with papillary renal cell carcinoma J Clin Oncol 31 2013 181 186.
25. A.D. Perera, E.V. Kleymenova, and C.L. Walker Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma Clin Cancer Res 6 2000 1518 1523.
26. M.S. Gordon, M. Hussey, and R.B. Nagle et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317 J Clin Oncol 27 2009 5788 5793.
27. J.A. Engelman, K. Zejnullahu, and T. Mitsudomi et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043.
28. A. Garcia, L. Rosen, and C.C. Cunningham et al. Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose J Clin Oncol 25 suppl 18S 2007 (abstract 3525).
29. I. Laux, J. Goldman, and R. Just et al. Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib Proceedings of ASCO 2009 Abstract 3549.
30. P.C. Ma, T. Kijima, and G. Maulik et al. c-MET mutational analysis in small-cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions Cancer Res 63 2003 6272 6281.